Log in

NASDAQ:SRPT - Sarepta Therapeutics Stock Price, Forecast & News

$97.82
-0.70 (-0.71 %)
(As of 04/1/2020 04:14 AM ET)
Today's Range
$95.46
Now: $97.82
$102.61
50-Day Range
$82.38
MA: $108.83
$125.44
52-Week Range
$72.05
Now: $97.82
$158.80
Volume978,100 shs
Average Volume924,365 shs
Market Capitalization$7.61 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.08
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company's pipeline comprise SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA. It has collaboration agreements with Nationwide Children's Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; Galgt2, a gene therapy program for the treatment of DMD; and Neutrophin 3, a gene therapy program to treat Charcot-Marie-Tooth neuropathies. The company also has a license agreement with Lysogene to develop LYS-SAF302, a gene therapy for mucopolysaccharidosis IIIA; a license and option agreement with Lacerta to develop treatments for CNS-targeted and lysosomal storage diseases; and research collaboration and option agreement with Genethon to develop micro-dystrophin gene therapy products. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a collaboration agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline; a strategic collaboration with Paragon Bioservices; and a strategic collaboration with CENTOGENE for the identification of patients with DMD in the Middle East and North Africa region. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Read More
Sarepta Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRPT
Previous SymbolNASDAQ:AVII
CUSIPN/A
Phone617-274-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$380.83 million
Book Value$10.98 per share

Profitability

Net Income$-715,080,000.00
Net Margins-187.77%

Miscellaneous

Employees499
Market Cap$7.61 billion
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive SRPT News and Ratings via Email

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.


Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

How has Sarepta Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Sarepta Therapeutics' stock was trading at $102.8150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SRPT stock has decreased by 4.9% and is now trading at $97.82. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Sarepta Therapeutics?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 1 hold rating and 23 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sarepta Therapeutics.

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Sarepta Therapeutics.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics Inc (NASDAQ:SRPT) issued its quarterly earnings data on Wednesday, February, 26th. The biotechnology company reported ($3.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.86) by $1.30. The biotechnology company earned $100.11 million during the quarter, compared to analyst estimates of $100.10 million. Sarepta Therapeutics had a negative net margin of 187.77% and a negative return on equity of 67.13%. During the same period in the previous year, the company earned ($2.05) earnings per share. View Sarepta Therapeutics' earnings history.

What price target have analysts set for SRPT?

24 Wall Street analysts have issued twelve-month target prices for Sarepta Therapeutics' shares. Their forecasts range from $160.00 to $260.00. On average, they anticipate Sarepta Therapeutics' share price to reach $196.36 in the next twelve months. This suggests a possible upside of 100.7% from the stock's current price. View analysts' price targets for Sarepta Therapeutics.

What are Wall Street analysts saying about Sarepta Therapeutics stock?

Here are some recent quotes from research analysts about Sarepta Therapeutics stock:
  • 1. Evercore ISI analysts commented, "We intend in connection with our next trial or set of trials associated with commercial material to address those issues and won’t move some of the restrictions that out of an overabundance or an abundance of caution exists within the protocol for what we call [indiscernible] (55:07) and now Study 102. So that our ultimate goal is to have the broadest possible coverage both of patients, age groups, geography but also genotype as well." (8/8/2019)
  • 2. According to Zacks Investment Research, "Sarepta's Exondys 51 has witnessed impressive growth in 2018. Sarepta is also focused on reimbursement programs for better accessibility of the drug. Moreover, a potential approval to golodirsen will boost the company’s prospect as it will increase eligible patient population. Sarepta’s continues to progress with its DMD pipeline. The company is collaborating with companies and academic institutions to boost its DMD pipeline. However, dependence on a single product, Exondys 51, remains a concern. Meanwhile in December 2018, the company received a setback as it failed to gain approval for Exondys 51 in the EU. The DMD market is getting competitive as several other companies are developing therapies. The company’s shares have underperformed the industry so far this year. Loss estimates have narrowed ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (5/8/2019)

Has Sarepta Therapeutics been receiving favorable news coverage?

News headlines about SRPT stock have trended very negative this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Sarepta Therapeutics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutSarepta Therapeutics.

Who are some of Sarepta Therapeutics' key competitors?

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Gilead Sciences (GILD), Netflix (NFLX), Advanced Micro Devices (AMD), Tesla (TSLA), Bausch Health Companies (BHC) and AbbVie (ABBV).

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the following people:
  • Mr. Douglas S. Ingram, Pres, CEO & Director (Age 56)
  • Mr. Sandesh Mahatme LL.M., Exec. VP, CFO & Chief Bus. Officer (Age 54)
  • Mr. David Tyronne Howton Jr., Exec. VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Mr. Alexander Bo Cumbo, Exec. VP & Chief Commercial Officer (Age 48)
  • Dr. Edward M. Kaye, Advisor (Age 70)

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $97.82.

How big of a company is Sarepta Therapeutics?

Sarepta Therapeutics has a market capitalization of $7.61 billion and generates $380.83 million in revenue each year. The biotechnology company earns $-715,080,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis. Sarepta Therapeutics employs 499 workers across the globe. View additional information about Sarepta Therapeutics.

What is Sarepta Therapeutics' official website?

The official website for Sarepta Therapeutics is http://www.sareptatherapeutics.com/.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]


MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ SRPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,303 (Vote Outperform)
Underperform Votes:  770 (Vote Underperform)
Total Votes:  2,073
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe SRPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel